Skip to main content

Atea Pharmaceuticals, Inc 10-Q for FY2026 Q3

Atea Pharmaceuticals, Inc. (AVIR)

10-Q 2026-11-09 For: 2026-09-30
View Original
Added on November 09, 2026

About this 10-Q

Atea Pharmaceuticals, Inc filed this 10-Q on November 9, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

BEM/RZR met C-BEYOND’s primary and secondary endpoints, achieving 93.9% SVR versus 94.8% for SOF/VEL. C-FORWARD topline results are expected in the first quarter 2027, followed by a targeted FDA submission in the second quarter 2027; funding is expected into mid-2028. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$32.16M
compared with a net loss of $42.05M a year earlier
Diluted EPS
-$0.40
compared with -$0.53 a year earlier